Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

(RTTNews) - Eli Lilly and Company (LLY) announced that the highest approved doses of Zepbound —12.5 mg and 15 mg — will soon be available in single-dose vials for $499 per month through ...